Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report

Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report

Blog Article

Alpelisib plus fulvestrant is a valid second or advanced line of treatment for patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who harbor an activating PIK3CA mutation.The well-known side effects of alpelisib are hyperglycemia, rash, and diarrhea.Herein, we report a case of a woman L-Citrulline who developed diffuse depigmented macules on the face, arms and legs, three months after initiating alpelisib.Both clinical and histopathological findings were consistent with new-onset vitiligo.To our knowledge, this is the first case described in literature which suggests a causal relationship between DEEP CLEANSE SHAMPOO alpelisib and irreversible dermatological adverse effect.